Wild type ROS1
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (2) | Wild type ALK, Wild type EGFR, Wild type ROS1 | Non-Small Cell Lung Cancer | Carboplatin, Cemiplimab, Pemetrexed | |
| EMA (1) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1 | Non-Small Cell Lung Cancer | Cemiplimab | |
| EMA (1) | PD-L1 >= 1%, Wild type ALK, Wild type EGFR, Wild type ROS1 | Non-Small Cell Lung Cancer | Carboplatin, Cemiplimab, Pemetrexed |